
April 24 (Reuters) - Ipsen SA IPN.PA:
ELAFIBRANOR SHOWS FAVORABLE SAFETY PROFILE AND EFFICACY IN PSC
A SIGNIFICANT IMPROVEMENT IN PRURITUS WAS OBSERVED IN PATIENTS ON ELAFIBRANOR 120 MG VERSUS PLACEBO
ELAFIBRANOR IMPROVES LIVER BIOCHEMICAL PARAMETERS IN PSC PATIENTS
PHASE II ELMWOOD TRIAL SHOWS POSITIVE SAFETY AND EFFICACY FOR ELAFIBRANOR
ELAFIBRANOR STABILIZES NON-INVASIVE MARKERS OF LIVER FIBROSIS